Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
Department of Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands.
Semin Nucl Med. 2017 Jul;47(4):322-351. doi: 10.1053/j.semnuclmed.2017.02.004. Epub 2017 Apr 12.
Positron emission tomography with the radiotracer F-fluoro-2-deoxy-d-glucose (FDG) plays an important role in the evaluation of bone pathology. However, FDG is not a cancer-specific agent, and knowledge of the differential diagnosis of benign FDG-avid bone alterations that may resemble malignancy is important for correct patient management, including the avoidance of unnecessary additional invasive tests such as bone biopsy. This review summarizes and illustrates the spectrum of benign bone conditions that may be FDG-avid and mimic malignancy, including osteomyelitis, bone lesions due to benign systemic diseases (Brown tumor, Erdheim-Chester disease, Gaucher disease, gout and other types of arthritis, Langerhans cell histiocytosis, and sarcoidosis), benign primary bone lesions (bone cysts, chondroblastoma, chondromyxoid fibroma, desmoplastic fibroma, enchondroma, giant cell tumor and granuloma, hemangioma, nonossifying fibroma, and osteoid osteoma and osteoblastoma), and a group of miscellaneous benign bone conditions (post bone marrow biopsy or harvest status, bone marrow hyperplasia, fibrous dysplasia, fractures, osteonecrosis, Paget disease of bone, particle disease, and Schmorl nodes). Several ancillary clinical and imaging findings may be helpful in discriminating benign from malignant FDG-avid bone lesions. However, this distinction is sometimes difficult or even impossible, and tissue acquisition will be required to establish the final diagnosis.
正电子发射断层扫描(PET)使用放射性示踪剂 F-氟代-2-脱氧-d-葡萄糖(FDG)在骨病理学评估中具有重要作用。然而,FDG 并非癌症特异性药物,了解良性 FDG 摄取性骨改变的鉴别诊断,这些改变可能类似于恶性肿瘤,对于正确的患者管理很重要,包括避免不必要的额外侵入性检查,如骨活检。本文综述并举例说明了可能为 FDG 摄取并模拟恶性肿瘤的良性骨病变谱,包括骨髓炎、良性全身性疾病引起的骨病变(棕色瘤、Erdheim-Chester 病、戈谢病、痛风和其他类型关节炎、朗格汉斯细胞组织细胞增生症、类肉瘤)、良性原发性骨病变(骨囊肿、成软骨细胞瘤、软骨粘液样纤维瘤、促结缔组织纤维瘤、软骨瘤、巨细胞瘤和骨母细胞瘤、血管瘤、非骨化性纤维瘤、骨样骨瘤和骨母细胞瘤)以及一组混杂的良性骨病变(骨髓活检或采集后状态、骨髓增生、纤维结构不良、骨折、骨坏死、骨关节炎、骨颗粒病和 Schmorl 结节)。一些辅助临床和影像学发现可能有助于鉴别良性和恶性 FDG 摄取性骨病变。然而,这种区分有时是困难的,甚至是不可能的,需要进行组织采集以确立最终诊断。